JP5148483B2 - 4−[(1,6−ジヒドロ−6−オキソ−2−ピリミジニル)アミノベンゾニトリルの製造方法 - Google Patents
4−[(1,6−ジヒドロ−6−オキソ−2−ピリミジニル)アミノベンゾニトリルの製造方法 Download PDFInfo
- Publication number
- JP5148483B2 JP5148483B2 JP2008512841A JP2008512841A JP5148483B2 JP 5148483 B2 JP5148483 B2 JP 5148483B2 JP 2008512841 A JP2008512841 A JP 2008512841A JP 2008512841 A JP2008512841 A JP 2008512841A JP 5148483 B2 JP5148483 B2 JP 5148483B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- formula
- alkyl
- process according
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 33
- -1 1,6-dihydro-6-oxo-2-pyrimidinyl Chemical group 0.000 title description 11
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 title description 2
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 239000000543 intermediate Substances 0.000 claims description 17
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 239000011541 reaction mixture Substances 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000005933 dealkoxycarbonylation reaction Methods 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- QWIKJMKYJNKLDW-UHFFFAOYSA-N OC(=O)N1CCC(=O)N=C1 Chemical compound OC(=O)N1CCC(=O)N=C1 QWIKJMKYJNKLDW-UHFFFAOYSA-N 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 125000005910 alkyl carbonate group Chemical group 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims description 2
- 238000005580 one pot reaction Methods 0.000 claims description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 14
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-trimethyl-phenylamino)-pyrimidin-2-ylamino]-benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HQABUPZFAYXKJW-UHFFFAOYSA-O butylazanium Chemical compound CCCC[NH3+] HQABUPZFAYXKJW-UHFFFAOYSA-O 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 150000002357 guanidines Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- BTDGLZSKNFJBER-UHFFFAOYSA-N 2-(4-cyanophenyl)guanidine Chemical compound NC(=N)NC1=CC=C(C#N)C=C1 BTDGLZSKNFJBER-UHFFFAOYSA-N 0.000 description 2
- BBNOJNASJQRRSH-UHFFFAOYSA-N 4-[(6-oxo-1h-pyrimidin-2-yl)amino]benzonitrile Chemical compound N1C(=O)C=CN=C1NC1=CC=C(C#N)C=C1 BBNOJNASJQRRSH-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- RHFZTBSULNJWEI-UHFFFAOYSA-N dimethyl 2-(methoxymethylidene)propanedioate Chemical compound COC=C(C(=O)OC)C(=O)OC RHFZTBSULNJWEI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JNRBSZUSHVFWIK-ONEGZZNKSA-N (e)-3-(4-amino-3,5-dimethylphenyl)prop-2-enenitrile Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1N JNRBSZUSHVFWIK-ONEGZZNKSA-N 0.000 description 1
- KWVPRPSXBZNOHS-UHFFFAOYSA-N 2,4,6-Trimethylaniline Chemical compound CC1=CC(C)=C(N)C(C)=C1 KWVPRPSXBZNOHS-UHFFFAOYSA-N 0.000 description 1
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- VLDSMCHWNWDAKQ-UHFFFAOYSA-N 2-methoxypropanedioic acid Chemical compound COC(C(O)=O)C(O)=O VLDSMCHWNWDAKQ-UHFFFAOYSA-N 0.000 description 1
- FQWBGZVXVRORRM-UHFFFAOYSA-N 2-pyrimidin-2-yloxypyrimidine Chemical class N=1C=CC=NC=1OC1=NC=CC=N1 FQWBGZVXVRORRM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IHXNIOYEXQWUNI-UHFFFAOYSA-N 4,5-dihydro-1h-pyrimidin-6-one Chemical compound O=C1CCN=CN1 IHXNIOYEXQWUNI-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
- BJJSUOOEBCCLNY-UHFFFAOYSA-N 4-iodo-2,6-dimethylaniline Chemical compound CC1=CC(I)=CC(C)=C1N BJJSUOOEBCCLNY-UHFFFAOYSA-N 0.000 description 1
- VCUVETGKTILCLC-UHFFFAOYSA-N 5,5-dimethyl-1-pyrroline N-oxide Chemical compound CC1(C)CCC=[N+]1[O-] VCUVETGKTILCLC-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BBNOJNASJQRRSH-UHFFFAOYSA-M N#Cc(cc1)ccc1Nc1nc([O-])ccn1 Chemical compound N#Cc(cc1)ccc1Nc1nc([O-])ccn1 BBNOJNASJQRRSH-UHFFFAOYSA-M 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- QSRFYFHZPSGRQX-UHFFFAOYSA-N benzyl(tributyl)azanium Chemical compound CCCC[N+](CCCC)(CCCC)CC1=CC=CC=C1 QSRFYFHZPSGRQX-UHFFFAOYSA-N 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical compound N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
Description
本発明は、反応工程が一容器工程(one−pot procedure)でありうる、4−オキソ−1,6−ジヒドロ−ピリミジニルカルボン酸エステル(II)から出発するまたはアルコキシ−メチレンマロン酸エステルと反応して(I)に転化されるエステル(II)となるグアニジン誘導体から出発する、4−[(1,6−ジヒドロ−6−オキソ−2−ピリミジニル)アミノベンゾニトリルの製造方法に関する。
後天性免疫不全症候群(エイズ)を引き起こすウイルスはヒト免疫不全ウイルス(HIV)として一般的に知られている。HIVの蔓延は世界中で重大な健康問題を引き起こしておりそして引き起こし続ける。多くのHIV阻害薬品が開発され、それらは現在ウイルスを撲滅するために使用されている。これらの薬品は、特に組み合わせ療法で使用される時には、ウイルスの抑制において有効であることが証明された。しかしながら、身体からウイルスを完全に排除しうる療法はない。
本発明はTMC278の合成における中間体の製造方法に関し、特に、それは式(II):
の4−オキソ−1,6−ジヒドロ−ピリミジニルカルボン酸エステルを脱アルコキシカルボニル化することにより式(I)の化合物を製造する式
に概略記述されている通りにして、式(III)のグアニジン誘導体を式(IV)のアルコキシメチレンマロン酸エステルと縮合させて以上で特定された中間体(II)を得、それを脱アルコキシカルボキシル化して式(I)の所望する最終生成物を得ることにより式(I)の化合物を製造する、以上で特定された式(I)の化合物の製造方法に関する。
TMC278は立体異性体形態で、より特にE−およびZ−異性体形態で生ずる。TMC278の好ましい形態はE−異性体、すなわち(E)−4−[[4−[[4−(2−シアノエテニル)−2,6−ジメチルフェニル]−アミノ]−2−ピリミジニル]−アミノ]−ベンゾニトリル(以下ではE−TMC278と称する)である。他の異性体はTMC278のZ−異性体、すなわち(Z)−4−[[4−[[4−(2−シアノエテニル)−2,6−ジメチルフェニル]−アミノ]−2−ピリミジニル]−アミノ]−ベンゾニトリル(これはZ−TMC278と称する)である。ここで「TMC278」と述べる場合には常に、E−形態、並びに優先的にE−形態を、例えば少なくとも80%の、特に少なくとも90%の、より特に少なくとも95%の、またはさらに少なくとも99%のE−形態を含有する両方の形態のいずれかの混合物をさす。
物の還流温度の範囲内の、特に約140℃〜約170℃の範囲内の、より特に約140℃〜約160℃の範囲内の温度において行うことができる。好ましくは、脱アルコキシカルボニル化反応はある時間、例えば約24〜120時間、または特に約24〜48時間、またはより特に約24〜36時間の期間にわたり行われる。1つの態様では、反応は高められた圧力において行われ、それにより例えば約200℃までのまたはマイクロ波加熱によるさらに高い温度を可能にする。これが反応時間を数時間、例えば約2〜6時間、の期間に短縮可能にする。
のピリミジニルオキシド塩を分解して、所望する式(I)の最終生成物を得ることが推定される。酸は好ましくは、例えば約100℃〜約150℃、特に約120℃〜約140℃の範囲内の如き高められた温度にある反応混合物に加えられる。
つ(II)から出発する最終生成物(I)の製造および(III)と(IV)との反応に関して以上で記載されたものと同じ反応条件を使用して行うことができる。
味する。
64g(0.4モル)の(4−シアノフェニル)グアニジン、98.4g(1.2モル)の酢酸ナトリウムおよび76.6g(0.44モル)の(メトキシメチレン)マロン酸ジメチルの600mlのN−メチルピロリドノン(NMP)中混合物を100℃に加熱しそして1時間にわたりこの温度において撹拌した。64.8mlの脱塩水を加えそして反応混合物を還流温度にさらに加熱した。反応混合物の温度が155℃〜160℃の範囲に達するまで約100mlの溶媒を蒸発させた。引き続き、反応混合物を30時間にわたり還流した。全体を20〜25℃に放冷しそして25gの濾過助剤を加えた。混合物を1時間にわたり20〜25℃において撹拌した後に、沈澱を濾別しそして40mlのNMPで洗浄した。溶媒を真空下で蒸留除去しそして残渣を120℃に加熱した。温度を130℃に保ちながら300mlの酢酸を(15分間にわたり)加熱された残渣に滴下した。酢酸の添加後に、混合物を150℃に加熱しそしてこの温度において15分間にわたり撹拌した。引き続き、混合物を20〜25℃に放冷した。生成した沈澱を濾別しそしてエタノール(1×200mlおよび1×80ml)で洗浄した。400mlのエタノールを洗浄された沈殿に加えそしてこの混合物を1時間にわたり加熱しそして還流した。20〜25℃に冷却した後に、沈澱を濾別し、100mlのエタノールで洗浄しそして50℃において真空下で16時間にわたり乾燥した。収量:65.6gの4−[(1,4−ジヒドロ−4−オキソ−2−ピリミジニル)−アミノ]ベンゾニトリル。
64g(0.4モル)の(4−シアノフェニル)グアニジン、98.4g(1.2モル)の酢酸ナトリウムおよび76.6g(0.44モル)の(エトキシメチレン)マロン酸ジエチルの600mlのN−メチルピロリドノン(NMP)中混合物を100℃に加熱しそして1時間にわたりこの温度において撹拌した。81mlの脱塩水を加えそして反応混合物を還流温度にさらに加熱した。反応混合物の温度が155℃〜160℃の範囲に達するまで約120mlの溶媒を蒸発させた。引き続き、反応混合物を72時間にわたり還流した。全体を20〜25℃に放冷しそして25gの濾過助剤を加えた。混合物を1時間にわたり20〜25℃において撹拌した後に、沈澱を濾別しそして50mlのNMPで洗浄した。溶媒を真空下で蒸留除去しそして残渣を130℃に加熱した。温度を130℃に保ちながら375mlの酢酸を(15分間にわたり)加熱された残渣に滴下した。酢酸の添加後に、混合物を150℃に加熱しそしてこの温度において15分間にわたり撹拌した。引き続き、混合物を20〜25℃に放冷した。生成した沈澱を濾別しそしてエタノール(1×250mlおよび1×100ml)で洗浄した。500mlのエタノールを洗浄された沈殿に加えそしてこの混合物を1時間にわたり加熱しそして還流した。20〜25℃に冷却した後に、沈澱を濾別し、100mlのエタノールで洗浄しそして50℃において真空下で16時間にわたり乾燥した。収量:80.5gの4−[(1,4−ジヒドロ−4−オキソ−2−ピリミジニル)−アミノ]ベンゾニトリル(75.9%収率)。
Claims (15)
- (I)を得るための(III)から(II)への転化を、中間体(II)の単離なしに、一容器反応(one−pot reaction)で行う請求項2に記載の方法。
- Rがメチルまたはエチルである請求項1または2に記載の方法。
- 塩の存在下で行う請求項1〜3のいずれかに記載の方法。
- 塩が式MXにより表示され、ここでMが金属またはアンモニウムもしくは置換されたアンモニウムであり、そしてXが親核性を有するアニオンである請求項4に記載の方法。
- Mがアルカリ金属、アンモニウムまたは置換されたアンモニウムであり、そしてXがハライド、シアニドまたはC1-4アルキルカルボキシレートである請求項5に記載の方法。
- Mがアルカリ金属であり、そしてXがC 1-4 アルキルカルボキシレートである請求項6に記載の方法。
- Mがナトリウムであり、そしてXがアセテートである請求項7に記載の方法。
- 双極性の非プロトン性溶媒中で行う請求項1〜4のいずれかに記載の方法。
- 溶媒がジメチルホルムアミド(DMF)、ジメチルアセトアミド(DMA)、ヘキサメチル燐酸トリアミド(HMPT)、N−メチルピロリドン(NMP)、ジメチルスルホキシド(DMSO)およびアセトニトリルから選択される請求項9に記載の方法。
- 溶媒がN−メチルピロリドンである請求項10に記載の方法。
- 脱アルコキシカルボニル化段階の終了時に酸を反応混合物に加える請求項1〜11のいずれかに記載の方法。
- 酸がアルキル炭酸である請求項12に記載の方法。
- 酸がC 1-4 アルキル炭酸である請求項13に記載の方法。
- 酸が酢酸である請求項14に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05104531.8 | 2005-05-26 | ||
EP05104531 | 2005-05-26 | ||
US68599305P | 2005-05-31 | 2005-05-31 | |
US60/685,993 | 2005-05-31 | ||
PCT/EP2006/062606 WO2006125809A1 (en) | 2005-05-26 | 2006-05-24 | Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino benzonitrile |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012229897A Division JP5580385B2 (ja) | 2005-05-26 | 2012-10-17 | 4−[(1,6−ジヒドロ−6−オキソ−2−ピリミジニル)アミノベンゾニトリルの製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008545680A JP2008545680A (ja) | 2008-12-18 |
JP5148483B2 true JP5148483B2 (ja) | 2013-02-20 |
Family
ID=35822492
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008512841A Active JP5148483B2 (ja) | 2005-05-26 | 2006-05-24 | 4−[(1,6−ジヒドロ−6−オキソ−2−ピリミジニル)アミノベンゾニトリルの製造方法 |
JP2012229897A Active JP5580385B2 (ja) | 2005-05-26 | 2012-10-17 | 4−[(1,6−ジヒドロ−6−オキソ−2−ピリミジニル)アミノベンゾニトリルの製造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012229897A Active JP5580385B2 (ja) | 2005-05-26 | 2012-10-17 | 4−[(1,6−ジヒドロ−6−オキソ−2−ピリミジニル)アミノベンゾニトリルの製造方法 |
Country Status (20)
Country | Link |
---|---|
US (2) | US8101752B2 (ja) |
EP (1) | EP1888537B1 (ja) |
JP (2) | JP5148483B2 (ja) |
CN (1) | CN101248051B (ja) |
AU (1) | AU2006251163C1 (ja) |
BR (1) | BRPI0611038B8 (ja) |
CA (1) | CA2609716C (ja) |
DK (1) | DK1888537T3 (ja) |
ES (1) | ES2437202T3 (ja) |
HK (1) | HK1123551A1 (ja) |
HR (1) | HRP20131133T1 (ja) |
IN (1) | IN2014DN04588A (ja) |
ME (1) | ME01612B (ja) |
MX (1) | MX2007014881A (ja) |
PL (1) | PL1888537T3 (ja) |
PT (1) | PT1888537E (ja) |
RS (1) | RS53062B (ja) |
RU (1) | RU2458056C2 (ja) |
SI (1) | SI1888537T1 (ja) |
WO (1) | WO2006125809A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1888537E (pt) * | 2005-05-26 | 2013-11-26 | Janssen R & D Ireland | Processo para preparar 4-[(1,6-dihidro-6-oxo-2-pirimidinil)amino benzonitrilo |
WO2012125993A1 (en) | 2011-03-17 | 2012-09-20 | Teva Pharmaceutical Industries Ltd. | Solid state forms of rilpivirine base, and rilipivirine salts |
ES2642383T3 (es) | 2012-03-13 | 2017-11-16 | Octapharma Ag | Procedimiento mejorado de producción de fibrinógeno y fibrinógeno producido por el mismo |
CN103058936B (zh) * | 2013-01-23 | 2016-01-06 | 宁波九胜创新医药科技有限公司 | 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法 |
CN103193719B (zh) * | 2013-04-08 | 2015-07-22 | 宁波九胜创新医药科技有限公司 | 一种4-[(4-羟基-2-嘧啶基)氨基]苯腈的制备方法 |
CN114933567B (zh) * | 2022-04-29 | 2023-07-11 | 武汉工程大学 | 一种2-甲硫基-4-嘧啶酮的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE63502B1 (en) * | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
RU2037483C1 (ru) * | 1989-07-20 | 1995-06-19 | Мерк Патент Гмбх | Способ получения замещенных ароматических нитрилов |
DE3923979A1 (de) | 1989-07-20 | 1991-01-24 | Merck Patent Gmbh | Verfahren zur herstellung von aromatischen nitrilen |
DE69905306T2 (de) * | 1998-03-27 | 2003-11-27 | Janssen Pharmaceutica Nv | HIV hemmende Pyrimidin Derivate |
NZ511116A (en) * | 1998-11-10 | 2003-08-29 | Janssen Pharmaceutica Nv | HIV replication inhibiting pyrimidines |
MXPA02003182A (es) * | 1999-09-24 | 2002-09-30 | Janssen Pharmaceutica Nv | Composiciones antivirales. |
AU782948B2 (en) * | 2000-05-08 | 2005-09-15 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
NZ531853A (en) * | 2001-11-01 | 2006-02-24 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
KR101140785B1 (ko) * | 2002-08-09 | 2012-05-03 | 얀센 파마슈티카 엔.브이. | 4-〔〔4-〔〔4-(2-시아노에테닐)-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법 |
CN1886380B (zh) * | 2003-09-30 | 2010-12-22 | 詹森药业有限公司 | 苯并咪唑化合物 |
PT1888537E (pt) * | 2005-05-26 | 2013-11-26 | Janssen R & D Ireland | Processo para preparar 4-[(1,6-dihidro-6-oxo-2-pirimidinil)amino benzonitrilo |
-
2006
- 2006-05-24 PT PT67552992T patent/PT1888537E/pt unknown
- 2006-05-24 IN IN4588DEN2014 patent/IN2014DN04588A/en unknown
- 2006-05-24 BR BRPI0611038A patent/BRPI0611038B8/pt active IP Right Grant
- 2006-05-24 CN CN2006800178794A patent/CN101248051B/zh active Active
- 2006-05-24 JP JP2008512841A patent/JP5148483B2/ja active Active
- 2006-05-24 EP EP06755299.2A patent/EP1888537B1/en active Active
- 2006-05-24 MX MX2007014881A patent/MX2007014881A/es active IP Right Grant
- 2006-05-24 SI SI200631704T patent/SI1888537T1/sl unknown
- 2006-05-24 PL PL06755299T patent/PL1888537T3/pl unknown
- 2006-05-24 WO PCT/EP2006/062606 patent/WO2006125809A1/en active Application Filing
- 2006-05-24 ME MEP-2013-136A patent/ME01612B/me unknown
- 2006-05-24 DK DK06755299.2T patent/DK1888537T3/da active
- 2006-05-24 RS RS20130528A patent/RS53062B/en unknown
- 2006-05-24 CA CA2609716A patent/CA2609716C/en active Active
- 2006-05-24 AU AU2006251163A patent/AU2006251163C1/en active Active
- 2006-05-24 RU RU2007148968/04A patent/RU2458056C2/ru active
- 2006-05-24 ES ES06755299.2T patent/ES2437202T3/es active Active
- 2006-05-24 US US11/913,200 patent/US8101752B2/en active Active
-
2009
- 2009-02-04 HK HK09100991.0A patent/HK1123551A1/xx unknown
-
2011
- 2011-12-14 US US13/325,621 patent/US8618291B2/en active Active
-
2012
- 2012-10-17 JP JP2012229897A patent/JP5580385B2/ja active Active
-
2013
- 2013-11-27 HR HRP20131133TT patent/HRP20131133T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CN101248051B (zh) | 2013-07-17 |
JP5580385B2 (ja) | 2014-08-27 |
BRPI0611038A2 (pt) | 2010-08-10 |
AU2006251163B2 (en) | 2012-03-08 |
US8101752B2 (en) | 2012-01-24 |
CA2609716C (en) | 2014-10-14 |
US20080171878A1 (en) | 2008-07-17 |
EP1888537B1 (en) | 2013-09-11 |
ES2437202T3 (es) | 2014-01-09 |
AU2006251163C1 (en) | 2012-07-12 |
HK1123551A1 (en) | 2009-06-19 |
RS53062B (en) | 2014-04-30 |
RU2458056C2 (ru) | 2012-08-10 |
BRPI0611038B8 (pt) | 2022-10-25 |
JP2013040194A (ja) | 2013-02-28 |
PL1888537T3 (pl) | 2014-02-28 |
US20120083606A1 (en) | 2012-04-05 |
EP1888537A1 (en) | 2008-02-20 |
US8618291B2 (en) | 2013-12-31 |
MX2007014881A (es) | 2008-02-15 |
CN101248051A (zh) | 2008-08-20 |
WO2006125809A1 (en) | 2006-11-30 |
AU2006251163A1 (en) | 2006-11-30 |
ME01612B (me) | 2014-09-20 |
JP2008545680A (ja) | 2008-12-18 |
DK1888537T3 (da) | 2013-12-09 |
SI1888537T1 (sl) | 2014-01-31 |
PT1888537E (pt) | 2013-11-26 |
BRPI0611038B1 (pt) | 2022-02-08 |
HRP20131133T1 (hr) | 2014-01-03 |
CA2609716A1 (en) | 2006-11-30 |
RU2007148968A (ru) | 2009-07-10 |
IN2014DN04588A (ja) | 2015-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5580385B2 (ja) | 4−[(1,6−ジヒドロ−6−オキソ−2−ピリミジニル)アミノベンゾニトリルの製造方法 | |
KR101086678B1 (ko) | 4-[[4-[[4-(2-시아노에테닐)-2,6-디메틸페닐]아미노]-2-피리미디닐]아미노]벤조니트릴의 제조방법 | |
RU2556986C2 (ru) | Способ синтеза диарилпиримидинового ненуклеозидного ингибитора обратной транскриптазы | |
US7511140B2 (en) | Process for preparing the calcium salt of rosuvastatin | |
JP3543709B2 (ja) | N−(アミノ−4,6−ジハロピリミジン)ホルムアミド類の製造方法 | |
WO2013059572A1 (en) | Process for the preparation of etravirine and intermediates in the synthesis thereof | |
JPH02225474A (ja) | 2,4―ジアミノ―6―ピペリジニル―ピリミジン―3―n―オキシドの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090508 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120417 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120717 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120724 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120817 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120824 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120914 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121017 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121113 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121128 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5148483 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151207 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |